Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a nasty disease with extremely high malignancy and poor prognosis. Annexin A3 (ANXA3) is a potential prognosis biomarker, displaying an excellent correlation of ANXA3 overexpression with patients' poor prognosis. Silencing the expression of ANXA3 effectiv...
Main Authors: | Yongxi Liang, Delin Min, Hulin Fan, Kunlin Liu, Juchuanli Tu, Xueyan He, Bingjie Liu, Lu Zhou, Suling Liu, Xun Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-04-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522004907 |
Similar Items
-
Identification of ANXA3 as a biomarker associated with pyroptosis in ischemic stroke
by: Linquan Liu, et al.
Published: (2023-12-01) -
Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family
by: Li-Hui Wang, et al.
Published: (2023-07-01) -
A Dominant-Negative Mutant of ANXA7 Impairs Calcium Signaling and Enhances the Proliferation of Prostate Cancer Cells by Downregulating the IP3 Receptor and the PI3K/mTOR Pathway
by: Meera Srivastava, et al.
Published: (2023-05-01) -
ANXA11 mutations are associated with amyotrophic lateral sclerosis–frontotemporal dementia
by: Yu Wang, et al.
Published: (2022-09-01) -
The role of Annexin A3 in coronary arterial lesions in children with Kawasaki disease
by: Mengling Li, et al.
Published: (2023-02-01)